Protagonist Therapeutics (PTGX) has released an update to notify the public and investors about an entry into a material definitive agreement.
Protagonist Therapeutics, Inc. and Takeda Pharmaceuticals USA, Inc. have entered into a Collaboration Agreement for the development, manufacture, and commercialization of rusfertide and other injectable hepcidin mimetics. The agreement stipulates shared development and commercialization responsibilities in the U.S., with Takeda managing these activities elsewhere. Protagonist Therapeutics will lead the Phase 3 VERIFY program, and Takeda will handle pre-commercialization and commercialization activities. Financially, Takeda will pay Protagonist an upfront fee, share profits, and provide milestone payments, with tiered royalties on sales outside the U.S. The agreement includes provisions for Protagonist to opt out of profit sharing and outlines governance structures, exclusivity terms, and conditions for termination.
For further insights into PTGX stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
